HICC: Humoral Immune Correlates for COVID19: Defining protective responses and critical readouts for Clinical Trials of Vaccines and Therapeutics

SARS-CoV-2是一种新出现的病毒，在有严重呼吸道症状的人中具有非常高的传染性和死亡风险。为了最大限度地成功保护人们免受这种疾病的侵袭，我们迫切需要了解并开发高精度的测试，以确定一个人何时产生了保护性免疫反应与新冠肺炎疾病反应。我们不了解轻度SARS-CoV-2感染患者和进展为危及生命的疾病的高危患者之间的抗体反应差异。了解具体的差异将有助于我们开发诊断严重疾病可能性的测试，并开发预防它们的疫苗。我们将利用尖端的高通量技术，详细确定SARS-CoV-2抗体在免疫保护中的功能作用，它们与疾病严重程度和感染后免疫持续时间的关系。重要的是，我们将把这些信息转化为测试，用于：1.确定NHS工作人员何时有证据表明对SARS-CoV-2的保护性抗体反应。这是管理NHS工作人员退还、指导公共卫生和政府政策的迫切需要。提供临床测试，以协助开发和评估用于治疗病情最重的患者的安全疫苗和治疗方法。

SARS-CoV-2 is an emerging virus with very high infectivity and risk of death in those with severe respiratory symptoms. To maximise our success in protecting people against this disease, we urgently need to understand and develop highly accurate tests to identify when a person has developed a protective immune response versus a COVID-19 disease response. We do not understand the antibody response differences between individuals who have mild SARS-CoV-2 infection and high risk patients that progress to life threatening disease. Understanding specific differences will help us develop tests to diagnose the likelihood of severe disease, and vaccines to prevent them. We will use cutting edge, high throughput technologies to identify in detail the functional role of SARS-CoV-2 antibodies in immune protection, their association with disease severity and the duration of immunity after infection. Importantly, we will turn this information into tests which will be used to:1. Identify when NHS-staff have evidence of protective antibody responses to SARS-CoV-2. This is urgently needed to manage NHS staff returns, guide public health and government policy.2. Provide clinical tests to assist the development and evaluation of safe vaccines and therapies for the treatment of the sickest patients.